Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University Sakura Medical Center, Chiba, Japan.
Division of Hematology and Oncology, Department of Medicine, Toho University Omori Medical Center, Tokyo, Japan.
J Cardiol. 2023 Dec;82(6):473-480. doi: 10.1016/j.jjcc.2023.07.006. Epub 2023 Jul 26.
It has been reported that early detection and treatment of cancer therapy- related cardiac dysfunction (CTRCD) improves its prognosis. The detailed relationships between electrocardiographic repolarization indices and decreased left ventricular function in CTRCD have not been elucidated. We closely assessed such relationships in patients with doxorubicin (DOX)-induced CTRCD.
This retrospective, single-center, cohort study included 471 consecutive patients with malignant lymphoma who received chemotherapy including DOX. Of them, 17 patients with CTRCD and 68 patients without CTRCD who underwent 12‑lead electrocardiogram and an echocardiogram before and after chemotherapy were eventually analyzed. The fluctuations of the following electrocardiographic repolarization indices were evaluated in lead V5: QT, JT, T peak to T end interval (Tp-e), and activation recovery interval (ARI). These indices were corrected by heart rate with the Fridericia formula.
The median period from the end of chemotherapy to the diagnosis of the CTRCD group was 346 days (IQR 170-1283 days). After chemotherapy, the QT interval was significantly prolonged in both with and without CTRCD groups compared with that before chemotherapy (pre QTc vs. post QTc in CTRCD group, 386 ± 27 ms vs. 411 ± 37 ms, p = 0.03, pre QTc vs. post QTc in non-CTRCD group, 388 ± 24 ms vs. 395 ± 25 ms, p = 0.04, respectively). ARIc after chemotherapy was characteristically observed only in the CTRCD group (pre ARIc vs. post ARIc in CTRCD group, 258 ± 53 ms vs. 211 ± 28 ms, p = 0.03, pre ARIc vs. post ARIc in non-CTRCD group, 221 ± 19 ms vs. 225 ± 23 ms, NS, respectively) and had negative correlations with left ventricular ejection fraction (r = -0.56, p < 0.001). Using the receiver-operating characteristic curve, the relationship between ARIc and CTRCD morbidity was examined. The optimal cut-off point of ARIc prolongation between before and after chemotherapy was 18 ms (sensitivity 75 %, specificity 79 %, area under the curve 0.76).
ARIc prolongation may be useful in the early detection of developing late-onset chronic DOX-induced CTRCD and lead to early treatment for cardiac protection.
据报道,早期发现和治疗癌症治疗相关的心脏功能障碍(CTRCD)可改善其预后。在 CTRCD 中,心电图复极指标与左心室功能下降之间的详细关系尚未阐明。我们在接受多柔比星(DOX)诱导的 CTRCD 的患者中密切评估了这种关系。
这是一项回顾性、单中心、队列研究,纳入了 471 例接受化疗包括 DOX 的恶性淋巴瘤连续患者。其中,17 例患有 CTRCD,68 例无 CTRCD,这些患者在化疗前后接受了 12 导联心电图和超声心动图检查。评估了 V5 导联中以下心电图复极指标的波动:QT、JT、Tp-e 峰至 Tp-e 结束间隔(Tp-e)和激活恢复间隔(ARI)。这些指标通过 Fridericia 公式与心率校正。
从化疗结束到 CTRCD 组诊断的中位时间为 346 天(IQR 170-1283 天)。化疗后,与化疗前相比,两组的 QT 间期均显著延长(CTRCD 组的化疗前 QTc 与化疗后 QTc,386±27ms 比 411±37ms,p=0.03;非 CTRCD 组的化疗前 QTc 与化疗后 QTc,388±24ms 比 395±25ms,p=0.04)。只有 CTRCD 组的 ARIc 在化疗后才具有特征性(CTRCD 组的化疗前 ARIc 与化疗后 ARIc,258±53ms 比 211±28ms,p=0.03;非 CTRCD 组的化疗前 ARIc 与化疗后 ARIc,221±19ms 比 225±23ms,NS),与左心室射血分数呈负相关(r=-0.56,p<0.001)。使用受试者工作特征曲线检查 ARIc 与 CTRCD 发病率之间的关系。化疗前后 ARIc 延长的最佳截断点为 18ms(灵敏度 75%,特异性 79%,曲线下面积 0.76)。
ARIc 延长可能有助于早期发现迟发性慢性 DOX 诱导的 CTRCD,并进行早期心脏保护治疗。